Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation

Completed · Not applicable · Has a placebo group

Conditions studied: Mild Cognitive Impairment

In brief

Patients with amnestic mild cognitive impairment (MCI) often have compromised quality of life (QOL). Cognitive impairment is a major contributor to decrements in QOL and progression of MCI often leads to loss of independence and withdrawal from social participation. MCI, in many patients, is an early expression of neurodegenerative disease. Patients with MCI frequently convert to Alzheimer's disease (AD) (12-16 percent by some estimates per year). Treatments for MCI are of limited scope and availability and of limited effectiveness. Thus, there is great need for treatments that can improve cognition and extend QOL in patients with MCI. The investigators propose to investigate the effect of a non-invasive and safe intervention that should have direct influence on brain systems underlying AD, transcutaneous vagal nerve stimulation (tVNS).

Key facts

Study ID
NCT03359902
Run by
University of Florida
People needed
59
Starts
2018-01-01
Expected to finish
2022-05-31
Last updated by the study team
2023-10-24

Who can join

Age: 60 and older, up to 89. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.